Cargando…

The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma

PURPOSE: To construct a prognostic index (PI) for overall survival (OS) to stratify nasopharyngeal carcinoma (NPC) into high-risk and low-risk groups. We also applied the model to investigate the role of the addition of adjuvant chemotherapy (AC) to concurrent chemoradiotherapy (CCRT) regimens for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Zhong-Guo, Zhang, Fan, Yu, Bin-Bin, Li, Ling, Qu, Song, Li, Ye, Guan, Ying, Liang, Ren-Ba, Han, Lu, Zhu, Xiao-Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007778/
https://www.ncbi.nlm.nih.gov/pubmed/32099476
http://dx.doi.org/10.2147/CMAR.S236128
_version_ 1783495368718155776
author Liang, Zhong-Guo
Zhang, Fan
Yu, Bin-Bin
Li, Ling
Qu, Song
Li, Ye
Guan, Ying
Liang, Ren-Ba
Han, Lu
Zhu, Xiao-Dong
author_facet Liang, Zhong-Guo
Zhang, Fan
Yu, Bin-Bin
Li, Ling
Qu, Song
Li, Ye
Guan, Ying
Liang, Ren-Ba
Han, Lu
Zhu, Xiao-Dong
author_sort Liang, Zhong-Guo
collection PubMed
description PURPOSE: To construct a prognostic index (PI) for overall survival (OS) to stratify nasopharyngeal carcinoma (NPC) into high-risk and low-risk groups. We also applied the model to investigate the role of the addition of adjuvant chemotherapy (AC) to concurrent chemoradiotherapy (CCRT) regimens for the treatment of NPC. METHODS: A prognostic model was established based on a retrospective study of 362 patients from January 2008 to June 2011. The discriminative and calibration abilities of the model were evaluated by Harrell’s concordance index (C-index), and calibration curves. Bootstrapping was used to perform for internal validation. External validation was conducted using 324 patients diagnosed with NPC from July 2011 to December 2012 at the same institution. Survival analyses were performed between CCRT-AC and CCRT alone groups for the high-risk and low-risk groups. RESULTS: The primary PI comprised covariates that were associated with OS in the training cohort, including T stage, N stage, age, and plasma alkaline phosphatase (ALP). Internal and external validation showed that the discrimination of the PI for OS was significantly better than that of the 8th edition AJCC staging system. Discretization by using a fixed PI score cut-off of 407.96 determined from the training data set yielded high- and low-risk subgroups with distinct OS outcomes in the validation cohort. Adjuvant chemotherapy improved OS in high-risk patients (HR 0.620, 95% CI 0.408 to 0.941; P = 0.023) but increased the risk of distant metastasis (HR, 4.222, 95% CI, 0.959 to 18.585; P = 0.038) in low-risk patients. CONCLUSION: The proposed prognostic model achieved good prediction and calibration of OS for patients with NPC. The addition of adjuvant chemotherapy might be a double-edged sword, bringing survival benefit to high-risk patients but greater risk of distant metastasis to low-risk patients.
format Online
Article
Text
id pubmed-7007778
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-70077782020-02-25 The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma Liang, Zhong-Guo Zhang, Fan Yu, Bin-Bin Li, Ling Qu, Song Li, Ye Guan, Ying Liang, Ren-Ba Han, Lu Zhu, Xiao-Dong Cancer Manag Res Original Research PURPOSE: To construct a prognostic index (PI) for overall survival (OS) to stratify nasopharyngeal carcinoma (NPC) into high-risk and low-risk groups. We also applied the model to investigate the role of the addition of adjuvant chemotherapy (AC) to concurrent chemoradiotherapy (CCRT) regimens for the treatment of NPC. METHODS: A prognostic model was established based on a retrospective study of 362 patients from January 2008 to June 2011. The discriminative and calibration abilities of the model were evaluated by Harrell’s concordance index (C-index), and calibration curves. Bootstrapping was used to perform for internal validation. External validation was conducted using 324 patients diagnosed with NPC from July 2011 to December 2012 at the same institution. Survival analyses were performed between CCRT-AC and CCRT alone groups for the high-risk and low-risk groups. RESULTS: The primary PI comprised covariates that were associated with OS in the training cohort, including T stage, N stage, age, and plasma alkaline phosphatase (ALP). Internal and external validation showed that the discrimination of the PI for OS was significantly better than that of the 8th edition AJCC staging system. Discretization by using a fixed PI score cut-off of 407.96 determined from the training data set yielded high- and low-risk subgroups with distinct OS outcomes in the validation cohort. Adjuvant chemotherapy improved OS in high-risk patients (HR 0.620, 95% CI 0.408 to 0.941; P = 0.023) but increased the risk of distant metastasis (HR, 4.222, 95% CI, 0.959 to 18.585; P = 0.038) in low-risk patients. CONCLUSION: The proposed prognostic model achieved good prediction and calibration of OS for patients with NPC. The addition of adjuvant chemotherapy might be a double-edged sword, bringing survival benefit to high-risk patients but greater risk of distant metastasis to low-risk patients. Dove 2020-02-04 /pmc/articles/PMC7007778/ /pubmed/32099476 http://dx.doi.org/10.2147/CMAR.S236128 Text en © 2020 Liang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Liang, Zhong-Guo
Zhang, Fan
Yu, Bin-Bin
Li, Ling
Qu, Song
Li, Ye
Guan, Ying
Liang, Ren-Ba
Han, Lu
Zhu, Xiao-Dong
The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma
title The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma
title_full The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma
title_fullStr The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma
title_full_unstemmed The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma
title_short The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma
title_sort double-edge role of the addition of adjuvant chemotherapy to concurrent chemoradiotherapy in the treatment of nasopharyngeal carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007778/
https://www.ncbi.nlm.nih.gov/pubmed/32099476
http://dx.doi.org/10.2147/CMAR.S236128
work_keys_str_mv AT liangzhongguo thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT zhangfan thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT yubinbin thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT liling thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT qusong thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT liye thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT guanying thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT liangrenba thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT hanlu thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT zhuxiaodong thedoubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT liangzhongguo doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT zhangfan doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT yubinbin doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT liling doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT qusong doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT liye doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT guanying doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT liangrenba doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT hanlu doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma
AT zhuxiaodong doubleedgeroleoftheadditionofadjuvantchemotherapytoconcurrentchemoradiotherapyinthetreatmentofnasopharyngealcarcinoma